Loading...
Open4.82
High5.95
Low4.5
Vol72.90M
P/EN/A
Mkt cap2.16B
52W H7.13
52W L0.46
Avg Vol11.54M
Div yieldN/A
Beta1.456
EPS-0.59
Loading...
Loading...
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2...